Search

Your search keyword '"Richard A. Pearson"' showing total 880 results

Search Constraints

Start Over You searched for: Author "Richard A. Pearson" Remove constraint Author: "Richard A. Pearson"
880 results on '"Richard A. Pearson"'

Search Results

1. Prediction and confirmation of a switch-like region within the N-terminal domain of hSIRT1

2. Important Crop Pollinators Respond Less Negatively to Anthropogenic Land Use Than Other Animals

3. Genomic analysis of Plasmodium vivax describes patterns of connectivity and putative drivers of adaptation in Ethiopia

4. Genomics of Plasmodium vivax in Colombia reveals evidence of local bottle-necking and inter-country connectivity in the Americas

5. Targeting the ribosome to treat multiple myeloma

6. Potential for positive biodiversity outcomes under diet-driven land use change in Great Britain [version 2; peer review: 2 approved]

7. Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum

8. Spatial analysis with SPIAT and spaSim to characterize and simulate tissue microenvironments

9. A molecular barcode and web-based data analysis tool to identify imported Plasmodium vivax malaria

10. Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma

11. Disseminated Cutaneous Leishmaniasis and Alcohol Misuse, Northeast Brazil, 2015–2018

12. Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy

13. Impacts of detritivore diversity loss on instream decomposition are greatest in the tropics

14. Cystathionine-β-synthase is essential for AKT-induced senescence and suppresses the development of gastric cancers with PI3K/AKT activation

15. Geographical distribution and genetic diversity of Plasmodium vivax reticulocyte binding protein 1a correlates with patient antigenicity.

16. CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

17. Water-quality and ecosystem impacts of recreation in streams: Monitoring and management

18. Genetic surveillance in the Greater Mekong subregion and South Asia to support malaria control and elimination

19. An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples [version 2; peer review: 2 approved]

20. An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples [version 1; peer review: 2 approved]

21. Emergence of artemisinin-resistant Plasmodium falciparum with kelch13 C580Y mutations on the island of New Guinea.

22. CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer

23. Genetic diversity and neutral selection in Plasmodium vivax erythrocyte binding protein correlates with patient antigenicity.

24. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

25. Genomic analysis of a pre-elimination Malaysian Plasmodium vivax population reveals selective pressures and changing transmission dynamics

27. High-Speed Infrared Measurement of Injector Tip Temperature during Diesel Engine Operation

28. KLF1 directly activates expression of the novel fetal globin repressor ZBTB7A/LRF in erythroid cells

29. The origins and relatedness structure of mixed infections vary with local prevalence of P. falciparum malaria

30. Somatic mutations in early metazoan genes disrupt regulatory links between unicellular and multicellular genes in cancer

31. Chloroquine resistance evolution in Plasmodium falciparum is mediated by the putative amino acid transporter AAT1

32. Supplementary Methods, Tables S1 - S3, Figure Legends from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma

33. Supplementary Figures and Tables from Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

34. Supplementary Methods from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study

35. Supplementary Methods from Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

36. Supplementary Table 5 from Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition

37. Data from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study

38. Data from Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition

39. Supplementary Figures 9-11 from The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ-Myc Lymphoma by Restoring Oncogene-Induced Senescence

40. Supplementary Figure S3 from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study

41. Supplementary Figure S2 from Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma

42. Supplementary Data 2 from Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

43. Supplementary Figures 7-8 from The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ-Myc Lymphoma by Restoring Oncogene-Induced Senescence

44. Supplementary Tables 1-2 from The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ-Myc Lymphoma by Restoring Oncogene-Induced Senescence

45. Supplementary Tables S1-S7 from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study

46. Supplementary Data from CX-5461 Sensitizes DNA Damage Repair–proficient Castrate-resistant Prostate Cancer to PARP Inhibition

47. Supplementary Table 1 from Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition

48. Supplementary Figures 1-3 from The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ-Myc Lymphoma by Restoring Oncogene-Induced Senescence

49. Supplementary Figure 12 from The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ-Myc Lymphoma by Restoring Oncogene-Induced Senescence

50. Supplementary Figures and Tables from Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition

Catalog

Books, media, physical & digital resources